Vestmark Advisory Solutions Inc. Lowers Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Vestmark Advisory Solutions Inc. reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 43.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 487 shares of the company’s stock after selling 368 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in IDEXX Laboratories were worth $201,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Insight Wealth Strategies LLC grew its stake in shares of IDEXX Laboratories by 230.5% in the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after purchasing an additional 7,041 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of IDEXX Laboratories by 17,238.5% in the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock valued at $1,139,000 after purchasing an additional 2,241 shares during the last quarter. Quest Partners LLC boosted its stake in shares of IDEXX Laboratories by 4,059.4% in the third quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock valued at $1,450,000 after buying an additional 2,801 shares in the last quarter. Crystal Rock Capital Management boosted its stake in shares of IDEXX Laboratories by 90.0% in the third quarter. Crystal Rock Capital Management now owns 9,005 shares of the company’s stock valued at $4,550,000 after buying an additional 4,265 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of IDEXX Laboratories by 3.4% in the third quarter. Victory Capital Management Inc. now owns 142,628 shares of the company’s stock valued at $72,059,000 after buying an additional 4,696 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on IDXX. Leerink Partners began coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. Morgan Stanley decreased their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Piper Sandler lifted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday. Finally, Bank of America lifted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Trading Up 0.3 %

Shares of NASDAQ IDXX opened at $430.12 on Monday. The stock’s 50 day moving average price is $437.37 and its two-hundred day moving average price is $449.09. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $562.25. The stock has a market capitalization of $34.98 billion, a P/E ratio of 40.31, a PEG ratio of 3.41 and a beta of 1.39. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.